Compounds > pimobendan
Page last updated: 2024-11-02

pimobendan and Cardiac Hypertrophy

pimobendan has been researched along with Cardiac Hypertrophy in 6 studies

pimobendan: produces arterial & venous dilatation in dogs; structure given in first source

Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.

Research Excerpts

ExcerptRelevanceReference
"Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated."9.22Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2016)
"Pimobendan has gained enormous importance in the treatment of mitral valve disease in dogs."6.90Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly. ( Bach, JP; Iwanuk, N; Nolte, I; Pilgram, A; Raue, J; Rohn, K; Rumstedt, K; Sehn, M; Wall, L, 2019)
"Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described."5.27Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Schummer, C; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2018)
"Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated."5.22Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2016)
"Pimobendan has gained enormous importance in the treatment of mitral valve disease in dogs."2.90Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly. ( Bach, JP; Iwanuk, N; Nolte, I; Pilgram, A; Raue, J; Rohn, K; Rumstedt, K; Sehn, M; Wall, L, 2019)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19901 (16.67)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Iwanuk, N1
Wall, L1
Nolte, I1
Raue, J1
Rumstedt, K1
Pilgram, A1
Sehn, M1
Rohn, K1
Bach, JP1
Boswood, A3
Gordon, SG2
Häggström, J2
Wess, G2
Stepien, RL2
Oyama, MA2
Keene, BW2
Bonagura, J2
MacDonald, KA2
Patteson, M3
Smith, S3
Fox, PR2
Sanderson, K2
Woolley, R2
Szatmári, V2
Menaut, P2
Church, WM2
O'Sullivan, ML2
Jaudon, JP2
Kresken, JG2
Rush, J2
Barrett, KA2
Rosenthal, SL2
Saunders, AB2
Ljungvall, I2
Deinert, M2
Bomassi, E2
Estrada, AH2
Fernandez Del Palacio, MJ2
Moise, NS2
Abbott, JA2
Fujii, Y2
Spier, A2
Luethy, MW2
Santilli, RA2
Uechi, M2
Tidholm, A2
Schummer, C1
Watson, P2
Otsuki, Y1
Nakamura, Y1
Harada, S1
Yamamoto, Y1
Ogino, K1
Morikawa, K1
Ninomiya, H1
Miyagawa, S1
Sawa, Y1
Hisatome, I1
Nishimura, M1
Blanchard, EM1
Mulieri, LA1
Alpert, NR1

Trials

3 trials available for pimobendan and Cardiac Hypertrophy

ArticleYear
Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
    PloS one, 2019, Volume: 14, Issue:10

    Topics: Animals; Cardiomegaly; Dog Diseases; Dogs; Echocardiography; Exercise Test; Female; Heart Murmurs; H

2019
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Journal of veterinary internal medicine, 2018, Volume: 32, Issue:1

    Topics: Animals; Cardiomegaly; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Heart Diseases; Hea

2018
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Journal of veterinary internal medicine, 2016, Volume: 30, Issue:6

    Topics: Animals; Cardiomegaly; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Failure; Male; Mitral V

2016

Other Studies

3 other studies available for pimobendan and Cardiac Hypertrophy

ArticleYear
Adipose stem cell sheets improved cardiac function in the rat myocardial infarction, but did not alter cardiac contractile responses to β-adrenergic stimulation.
    Biomedical research (Tokyo, Japan), 2015, Volume: 36, Issue:1

    Topics: Adipocytes; Animals; Atrial Natriuretic Factor; Atrial Remodeling; Bucladesine; Cardiomegaly; Cell D

2015
Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease.
    The Veterinary record, 2011, Feb-26, Volume: 168, Issue:8

    Topics: Animals; Cardiomegaly; Cardiotonic Agents; Clinical Trials as Topic; Dog Diseases; Dogs; Mitral Valv

2011
The effects of acute and chronic inotropic interventions on tension independent heat of rabbit papillary muscle.
    Basic research in cardiology, 1987, Volume: 82 Suppl 2

    Topics: Animals; Cardiomegaly; Cardiotonic Agents; Heart; In Vitro Techniques; Isoproterenol; Myocardial Con

1987